Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRISPR-TIL in Metastatic Melanoma
NCT06783270Phase 1Recruiting
- Start
- Dec 2024
- Primary completion
- Jan 2027
- Modality
- Gene Silencing, CRISPR-Cas9, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PDCD1-edited tumor-infiltrating lymphocytes in melanoma. Primary endpoints: Feasibility and Incidence rate of treatment-emergent adverse events at 3 months. Started Dec 2024; status: recruiting.
02
Drugs
PDCD1-edited tumor-infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06783270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06783270.